Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer

The androgen receptor (AR) is widely expressed in breast cancer (BC) and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in pre-clinical models and clinical trials of prostate cancer, and are currently being...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Gordon, Michael A., D'Amato, Nicholas C., Gu, Haihua, Babbs, Beatrice, Wulfkuhle, Julia, Petricoin, Emanuel F., Gallagher, Isela, Dong, Ting, Torkko, Kathleen, Liu, Bolin, Elias, Anthony, Richer, Jennifer K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517319/
https://ncbi.nlm.nih.gov/pubmed/28468774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0111
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados